World Molecular Imaging Congress focuses on HuMab 5B1 antibody

World Molecular Imaging Congress focuses on HuMab 5B1 antibody.
World Molecular Imaging Congress focuses on HuMab 5B1 antibody. | Courtesy of medicalexpo.com
MabVax Therapeutics Holdings Inc., a clinical stage oncology drug development company, recently announced that its top antibody, HuMab 5B1, will be the main focus at the World Molecular Imaging Congress (WMIC).

The company’s antibody will be the focus of five individual presentations during the congress. Researchers at the Department of Radiology of Memorial Sloan Kettering Cancer Center will be unveiling the results of using the top antibody as both a radioimmunotherapy agent and a PET imaging agent for pancreatic cancer.

Current pancreatic cancer rates amount to just five percent of all of the patients who are first diagnosed with metastatic diseases. There are five-year survival rates for this cancer. These factors make it difficult to identify the metastases that are not detected. It also makes it challenging to create advance therapeutics for this cancer.

Researchers at MSK are using the most advanced technology to create an innovative generation of therapeutic and diagnostic agents with HuMab 5B1.

Ongoing students will show whether the broad technology platform is useful as an imaging as well as a therapeutic agent.

Presenters of HuMab’s antibody include Jacob Houghton (Ph.D. of MSK), Dalya Abdel-Atti, Jan-Philip Meyer, PhD and Ryan Lanning, M.D., Ph.D.

The event will be held in Hawaii from Sept. 2 to 5, 2015.